Giacomo Aimar
Overview
Explore the profile of Giacomo Aimar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
49
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Marandino L, Trastu F, Ghisoni E, Lombardi P, Mariniello A, Reale M, et al.
BMJ Oncol
. 2025 Jan;
2(1):e000021.
PMID: 39886519
Objective: To assess time trends in the inclusion of health-related quality of life (QoL) among study endpoints and in the reporting of QoL results in study publications, randomised phase III...
2.
Numico G, Ferrua R, Fea E, Giamello J, Colantonio I, Occelli M, et al.
BMJ Support Palliat Care
. 2023 Sep;
PMID: 37704262
Objectives: Hospital admission (HA) in cancer history is a common, repeated and frequently unplanned event. The emergency departments (EDs) and the oncological outpatient service (OOS) are the ordinary way of...
3.
Rossi A, Aimar G, Audisio M, Bungaro M, Caglio A, Di Liello R, et al.
Eur J Cancer
. 2023 Jun;
189:112920.
PMID: 37277262
Introduction: Randomised controlled trials (RCTs) are usually considered the highest level of evidence for clinical practice. Patients assigned to control arm in RCTs should always receive the best available treatments...
4.
Lombardi P, Aimar G, Peraldo-Neia C, Bonzano A, Depetris I, Fenocchio E, et al.
Oncol Rep
. 2022 Dec;
49(2).
PMID: 36562382
Fluoropyrimidines (FP) are the backbone chemotherapy in colorectal cancer (CRC) treatment; however, their use is associated with cardiotoxicity, which is underreported. In the present study, it was aimed to prospectively...
5.
Aimar G, Paratore C, Zichi C, Marino D, Sperti E, Caglio A, et al.
Explor Target Antitumor Ther
. 2022 Sep;
2(5):448-464.
PMID: 36045702
Patients with unresectable biliary tract carcinomas (BTCs) have a poor prognosis with a median overall survival of fewer than 12 months following systemic chemotherapy. In recent years, the identification of...
6.
Mentrasti G, Cantini L, Zichi C, DOstilio N, Gelsomino F, Martinelli E, et al.
Oncologist
. 2022 Jul;
27(9):e723-e730.
PMID: 35815922
Background: Coronavirus disease 2019 (COVID-19) has triggered the disruption of health care on a global scale. With Italy tangled up in the pandemic response, oncology care has been largely diverted...
7.
Antonetti P, Fargnoli M, Porzio G, Salvatore L, Filippi R, Ghidini M, et al.
Support Care Cancer
. 2021 Nov;
30(3):2455-2465.
PMID: 34779921
Background: Skin toxicity in patients affected by metastatic colorectal cancer (mCRC) treated with epidermal growth factor receptor (EGFR) inhibitors is well known. However, ad hoc ESMO guidelines have only recently...
8.
Parisi A, Cortellini A, Venditti O, Filippi R, Salvatore L, Tortora G, et al.
Front Oncol
. 2021 Nov;
11:712053.
PMID: 34778029
Background: Few data regarding post-induction management following first-line anti-epidermal growth factor receptor (EGFR)-based doublet regimens in patients with left-sided wild-type metastatic colorectal cancer (mCRC) are available. Methods: This multicenter, retrospective...
9.
Parisi A, Porzio G, Cannita K, Venditti O, Avallone A, Filippi R, et al.
Clin Colorectal Cancer
. 2021 Aug;
20(4):318-325.
PMID: 34380594
Background: Doublets plus antiepidermal growth factor receptors monoclonal antibodies (EGFRi) are widely considered the preferable first-line regimen in patients with left-sided RAS/BRAF wild-type metastatic colorectal cancer (mCRC), resulting superior in...
10.
Casadei-Gardini A, Filippi R, Rimini M, Rapposelli I, Fornaro L, Silvestris N, et al.
Oncology
. 2021 Feb;
99(5):292-299.
PMID: 33626532
Background And Aims: In the last few years, there has been increasing interest in non-cancer medications and their potential anti-cancer activity. Data are not available in cholangiocarcinoma (CCA) patients. The...